Phase I Trial Evaluates Pevonedistat-Capecitabine-Oxaliplatin Combination for Advanced Gastric Cancer
Key Insights
A phase I study investigated pevonedistat, a first-in-class NEDD8-activating enzyme (search) inhibitor, combined with capecitabine and oxaliplatin in patients with advanced gastric cancer (search).
The research builds on previous findings showing that neddylation inhibitor MLN4924 (pevonedistat) suppresses growth and migration of human gastric cancer (search) cells in laboratory studies.
The combination represents a novel therapeutic approach targeting the ubiquitin-proteasome pathway in gastric cancer (search), which remains a significant global health burden.
A phase I clinical trial has evaluated the safety and efficacy of pevonedistat combined with capecitabine and oxaliplatin in patients with advanced gastric cancer (search), representing a novel approach to targeting the ubiquitin-proteasome pathway in this challenging malignancy.
Novel Mechanism of Action
Pevonedistat (MLN4924) is a first-in-class NEDD8-activating enzyme (search) inhibitor that targets the neddylation pathway, a critical post-translational modification system involved in cancer cell survival and proliferation. Previous research has demonstrated that neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer (search) cells, providing the scientific rationale for this clinical investigation.
The drug works by inhibiting the NEDD8-activating enzyme (search), which plays a crucial role in the regulation of SCF E3 ubiquitin ligases (search). These enzymes have been identified as potential anticancer targets and biomarkers, with E3 ubiquitin ligases serving as important regulators of cell-cycle control and cancer development.
Clinical Development Program
The gastric cancer (search) study is part of a broader clinical development program for pevonedistat across multiple cancer types. Previous phase I studies have established the safety profile of pevonedistat as a single agent and in combination with other therapies in patients with acute myeloid leukemia (search) and myelodysplastic syndromes (search).
Additional investigations have explored pevonedistat in combination with azacitidine in patients with AML, showing promising activity. The drug has also been studied in combination with docetaxel, carboplatin, paclitaxel, and gemcitabine in patients with advanced solid tumors, demonstrating its potential versatility across different cancer types.
Treatment Landscape Context
Gastric cancer (search) represents a significant global health challenge, with current treatment options including various chemotherapy combinations and immunotherapy approaches. Standard treatments include oxaliplatin-based regimens, with studies showing efficacy of oxaliplatin combined with S-1 or capecitabine in advanced gastric cancer patients.
Recent advances have incorporated immunotherapy into the treatment paradigm, with nivolumab plus chemotherapy and pembrolizumab plus chemotherapy showing improved outcomes in HER2 (search)-negative advanced gastric cancer (search). For heavily pretreated patients, options include trifluridine/tipiracil and trastuzumab deruxtecan for HER2-positive disease.
Safety Considerations
The combination of capecitabine and oxaliplatin carries known toxicity profiles that require careful monitoring. Oxaliplatin-based chemotherapy has been associated with severe hepatic sinusoidal obstruction and steatohepatitis, particularly in patients with colorectal cancer (search) liver metastases. Capecitabine can cause drug-induced liver injury, and the combination has been linked to various toxicities including cardiotoxicity and steatohepatitis in some patients.
Broader Clinical Applications
Pevonedistat's clinical development extends beyond gastric cancer (search), with studies in East Asian patients with acute myeloid leukemia (search) or myelodysplastic syndromes (search) demonstrating acceptable safety and pharmacokinetic profiles. Pediatric studies have also been conducted, evaluating the drug in combination with chemotherapy in patients with recurrent or refractory solid tumors.
A phase II trial of pevonedistat and docetaxel in patients with previously treated advanced non-small-cell lung cancer (search) has also been completed, further expanding the potential applications of this novel therapeutic approach.
The investigation of pevonedistat in gastric cancer (search) represents an important step in exploring targeted therapies that address the underlying molecular mechanisms driving cancer progression, potentially offering new hope for patients with this challenging disease.